<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022043</url>
  </required_header>
  <id_info>
    <org_study_id>34817/7/21</org_study_id>
    <nct_id>NCT05022043</nct_id>
  </id_info>
  <brief_title>Serum Presepsin as Early Predictor for Neonatal Early-onset Sepsis</brief_title>
  <official_title>At Admission Serum Presepsin as Early Predictor for Disease Severity and Positive Blood Culture for Neonates With Early-onset Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      124 neonates aged ≤7 days with suspected EOS were clinically evaluated using SNAP-II and gave&#xD;
      blood samples for BC, total leucocytic count (TLC), lymphocytic and neutrophil count, and&#xD;
      ELISA estimation of serum levels of PSP, procalcitonin (PCT), and tumor necrosis factor-α&#xD;
      (TNF-α). Enrolled neonates were categorized as Confirmed EOS: neonates with evident clinical&#xD;
      sepsis manifestations and positive BC, Suspected EOS: neonates with evident clinical sepsis&#xD;
      manifestations but had negative BC and No EOS included neonates free of evident clinical&#xD;
      sepsis manifestations, had negative BC and showed no deterioration till 72-hr after&#xD;
      admission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prediction of neonatal outcome</measure>
    <time_frame>one week</time_frame>
    <description>Ability of Serum Presepsin to disseminate neonates with confirmed EOS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Neonatal Sepsis</condition>
  <arm_group>
    <arm_group_label>EOS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NO-EOS</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum Presepsin</intervention_name>
    <description>Estimation of Serum Presepsin at time of admission</description>
    <arm_group_label>EOS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  included gestational age (GA) of 28-41 weeks and 5-min APGAR score of ≥7, and neonatal&#xD;
             age of &lt;7 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  including small for gestational age, presence of a chromosomal abnormality, multiple&#xD;
             congenital anomalies, genetic syndromes, history of premature rupture of membranes,&#xD;
             chorioamnionitis, neonatal asphyxia, and missed inclusion criterion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tanta university</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 21, 2021</last_update_submitted>
  <last_update_submitted_qc>August 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Mohamed B.Hamza</investigator_full_name>
    <investigator_title>lecturer of pediatrics and neonatology</investigator_title>
  </responsible_party>
  <keyword>Early-onset neonatal sepsis</keyword>
  <keyword>Presepsin</keyword>
  <keyword>Clinical scoring</keyword>
  <keyword>Early predictors</keyword>
  <keyword>Blood culture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

